Tag Archive for: POLB 001

Poolbeg Pharma plc – POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

/in

RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part by MRC grant Poolbeg will act as the lead business partner alongside Johnson & Johnson and other partners 8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that […]

Read more

Poolbeg Pharma plc – POLB 001 European Patent granted

/in

Further strengthens Poolbeg’s global intellectual property portfolio 20 November 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the European Patent Office has granted Poolbeg’s European Immunomodulator II patent application covering POLB 001 for the treatment of severe influenza. Read more…

Read more

Poolbeg Pharma plc – Interim Results for the six months to 30 June 2025

/in

Well-funded with multiple upcoming clinical milestones 29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025. Read more…

Read more

Poolbeg Pharma plc – ACT appointed for POLB 001 Phase 2a Trial and supply of approved bispecific antibody drug secured at no cost

/in

Trial to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres  25 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (“ACT”), to […]

Read more

Poolbeg Pharma plc – Poolbeg granted FDA Orphan Drug Designation for POLB 001

/in

27 May 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that the US Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (“CRS”). Read more…

Read more